

Synthesis and antibacterial activity of novel (3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)aryl methanones

¹ Manasa HS, ¹ Shashikanth S* and ² Anil Kumar M.

¹ Department of Studies in Chemistry, University of Mysore, Mysore, India

² Department of Microbiology and Biotechnology, Bangalore University, Bangalore, India

* Corresponding Author: E-Mail: shashis1956@gmail.com

Received: 05 Oct 2015, Revised and Accepted: 23 Oct 2015

ABSTRACT

In the present study, a series of novel (3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)aryl methanones (8a-l), were synthesized by condensing 5-(chloromethyl)-3-aryl-1,2,4-oxadiazole (7(a-f)) with aryl (3-hydroxy-2, 4-dimethoxyphenyl) methanones (4a-b) using K_2CO_3 . The chemical structure of the newly synthesized compounds was characterized by analytical and spectral (1H NMR, ^{13}C NMR and HRMS) techniques. The title compounds were screened for qualitative (zone of inhibition) by agar well technique, respectively. Among the synthesized compounds in the series, the compounds 8b, 8c, 8f and 8l were found to exhibit significant antibacterial activity at lower concentration, against Gram positive bacteria such as *Bacillus subtilis*, *Staphylococcus aureus* and Gram negative bacteria such as *Salmonella typhimurium*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. The rest of the compounds showed moderate antibacterial activity when compared to the standard positive controls Chloramphenicol.

Keywords: 2,6-dimethoxy phenol, aryl (3-hydroxy-2, 4-dimethoxyphenyl) methanones, (3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)aryl methanones, antibacterial activity.

1. INTRODUCTION

Heterocycles are well represented in both natural products and pharmaceuticals, where nitrogen heterocycles are very important. In the field of medicinal chemistry, the research work has been done on biologically active molecules based on molecular recognition, which has allowed us to review thoroughly the material included in the earlier stage to make amendments in the light of new knowledge and to include in the recent work. Heterocyclic compounds containing five-membered ring, in particular 1,2,4-oxadiazole possess versatile biological properties such as antibacterial [1], anticonvulsant, anti-inflammatory [2], antiallergic [3], anticancer [4], antifungal [5], antihistaminic [6], activities.

The benzophenone analogues have been synthesized by adopting A. Ghinet et al [7-10] procedure. The structural features of benzophenones form the prominent position in organic chemistry and of at most practical and theoretical importance. Functionalized phenols such as 3-hydroxy benzophenones represent

important building blocks in medicinal and organic chemistry due to their contribution. The polar nature of the carbonyl group possesses biological and chemical properties which are extensively studied. As a result, great deals of research activities are carried out in several laboratories. Benzophenone analogues have displayed versatile biological activities such as anti-microbial, anti-cancer, anti-convulsant, anti-pyretic, anti-hypertensive, anti-diabetic, anti-inflammatory and analgesic by their polar feature of carbonyl group. Benzophenone is used as an ultraviolet (UV)-curing agent in sunglasses, and to prevent UV light from damaging scents and colors in products such as perfumes and soaps. Besides, benzophenones occur naturally in food such as Muscat grape and mango.

Methodologies for synthesizing the core heterocycle linked benzophenones mainly rely upon, Friedel craft's acylation, coupling of hydroxyl benzophenones with 1,2,4-oxadiazoles using K_2CO_3 . This leads us to incorporate both the bioactive molecules in a single molecular frame to determine the additive effect towards the

antibacterial activity. In recent years, the synthesis of heterocyclic compounds linking multi-structure in a molecule has received considerable interest in organic chemistry.

2. MATERIALS AND METHODS

2.1. Chemistry

All the solvents and reagents used were of AR grade and commercially available; used as such without further purification. All melting points were taken in open capillary tube and are uncorrected. The ^1H NMR spectra were recorded on Shimadzu AMX 400-Bruker, 400 MHz spectrometer using CDCl_3 as a solvent and TMS as internal standard (chemical shift δ in ppm). The Elemental (C, H, N) analyses were obtained on Vario EL III Elementar. Silica gel column chromatography was performed using Merck Silica gel (100-200 mesh) and Merck made TLC plates were used for reaction monitoring. Mass spectra were recorded on LCMS Agilent 1100 series with MSD (ion trap) using 0.1% aqueous TFA in acetonitrile system on C18-BDS Column for 10 min duration.

2.2. General Procedure for the Synthesis of (3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)(4-methoxyaryl)methanones (8a-l)

To a solution of 5-(chloromethyl)-3-aryl-1,2,4-oxadiazole (**7a-f**) and (3-hydroxy-2,4-dimethoxyphenyl)aryl methanone (**4a-d**) in DMF was added K_2CO_3 . The reaction mixture was refluxed for 4 h and the completion of the reaction was monitored through thin layer chromatography. The reaction mixture was cooled and carefully poured into crushed ice and allowed for stirring. The aqueous solution was extracted with diethyl ether; the organic layer was washed with brine solution, dried over sodium sulfate and concentrated under reduced pressure to get the crude product. The crude product was purified by column chromatography using petroleum ether: ethyl acetate as an eluent to afford (2,4-dimethoxy-3-((3-phenyl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)(4-methoxyaryl)methanones (**8a-l**).

2.3. Typical Procedure for the Synthesis of 3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)(4-methoxyaryl)methanones **8c**

To a solution of 5-(chloromethyl)-3-aryl-1,2,4-oxadiazole **7a** (0.25g, 0.8mmol) and (3-hydroxy-2,4-dimethoxyphenyl)aryl methanone **4a** (1.05g, 0.8mmol) in 5ml of DMF was added K_2CO_3 (0.34g, 2.46mmol). The reaction mixture was then refluxed for 4h and concentrated to get crude product. The reaction mixture was cooled and

carefully poured into crushed ice and allowed for stirring. The aqueous solution was extracted with diethyl ether, the organic layer was washed with brine solution, dried over sodium sulfate and concentrated under reduced pressure to get the crude product. This crude product was purified by column chromatography on silica gel 60:120 and petroleum ether: ethyl acetate as an eluent to afford 0.6g (80%) (2,4-dimethoxy-3-((3-phenyl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)(4-methoxyaryl)methanone **8c** as a white solid.

^1H NMR (CDCl_3) δ ppm: 3.74 (s, 3H), 3.82 (s, 3H), 3.85 (s, 3H), 5.32 (s, 2H, methylene -H), 6.65 (d, 1H), 6.89 (d, 3H), 7.25 (m, 3H), 7.97 (d, 2H), 8.21 (d, 2H), MS: m/z = 447.2 (M+1). Anal. Calcd for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_6$: C, 67.26; H, 4.97; N, 6.27; O, 21.50; Found: C, 67.40; H, 4.71; N, 6.28; O, 21.61.

2.3.1. 3-((3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)methoxy)-2,4-dimethoxyphenyl)(4-methoxyaryl)methanone (**8a**)

^1H NMR (CDCl_3) δ ppm: 3.76 (s, 3H), 3.84 (s, 3H), 3.89 (s, 3H), 5.33 (s, 2H, methylene -H), 6.75 (d, 1H), 6.87 (d, 2H), 7.17 (m, 3H), 7.77 (d, 2H), 8.10 (d, 2H), MS: m/z = 465.0 (M+1). Anal. Calcd for $\text{C}_{25}\text{H}_{21}\text{FN}_2\text{O}_6$: C, 64.65; H, 4.56; F, 4.09; N, 6.03; O, 20.67; Found: C, 64.70; H, 4.51; F, 4.04; N, 6.08; O, 20.67.

2.3.2. 2,4-dimethoxy-3-((3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)(4-methoxyaryl)methanone (**8b**)

^1H NMR (CDCl_3) δ ppm: 3.78 (s, 3H), 3.86 (s, 3H), 3.89 (s, 3H), 5.36 (s, 2H, methylene -H), 6.75 (d, 1H), 6.87 (d, 2H), 7.17 (m, 3H), 7.77 (d, 2H), 8.10 (d, 2H), MS: m/z = 515.1 (M+1). Anal. Calcd for $\text{C}_{26}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_6$: C, 60.70; H, 4.11; F, 11.08; N, 5.45; O, 18.66; Found: C, 60.65; H, 4.15; F, 11.04; N, 5.58; O, 18.67.

2.3.3. (3-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methoxy)-2,4-dimethoxyphenyl)(4-methoxyaryl)methanone (**8d**)

^1H NMR (CDCl_3) δ ppm: 3.75 (s, 3H), 3.84 (s, 3H), 3.89 (s, 3H), 5.33 (s, 2H, methylene -H), 6.75 (d, 1H), 6.87 (d, 2H), 7.17 (d, 1H), 7.46 (d, 2H), 7.77 (d, 2H), 8.04 (d, 2H), MS: m/z = 481.1, (M+1): 483.1 (M+3). Anal. Calcd for $\text{C}_{25}\text{H}_{21}\text{ClN}_2\text{O}_6$: C, 62.44; H, 4.40; Cl, 7.37; N, 5.83; O, 19.85; Found: C, 62.40; H, 4.54; Cl, 7.34; N, 5.89; O, 19.94.

2.3.4. 2,4-dimethoxy-3-((3-phenyl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)(aryl)methanone (**8e**)

^1H NMR (CDCl_3) δ ppm: 3.84 (s, 3H), 3.89 (s, 3H), 5.35 (s, 2H, methylene -H), 6.73 (d, 2H), 6.87 (d, 1H), 7.36 (m, 5H), 7.77 (d, 2H), 8.04 (d,

2H), MS: $m/z = 417.1(M+1)$. Anal. Calcd for $C_{24}H_{20}N_2O_5$: C, 69.22; H, 4.84; N, 6.73; O, 19.21; Found: C, 69.20; H, 4.74; N, 6.83; O, 19.24.

2.3.5. 3-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methoxy)-2,4-dimethoxyphenyl (phenyl) methanone (8f)

$^1\text{H NMR}$ (CDCl_3) δ ppm: 3.84 (s, 3H), 3.89 (s, 3H), 5.35 (s, 2H, methylene -H), 6.73 (d, 1H), 6.87 (d, 1H), 7.36 (m, 5H), 7.77 (d, 2H), 8.04 (d, 2H), MS: $m/z = 451.1 (M+1)$. Anal. Calcd for $C_{24}H_{19}ClN_2O_5$: C, 63.93; H, 4.25; Cl, 7.86; N, 6.21; O, 17.74; Found: C, 63.90; H, 4.27; Cl, 7.80; N, 6.23; O, 17.24.

2.3.6. 2,4-dimethoxy-3-((3-(p-tolyl)-1,2,4-oxadiazol-5-yl) methoxy) phenyl (aryl) methanone (8g)

$^1\text{H NMR}$ (CDCl_3) δ ppm: 2.23 (s, 3H), 3.84 (s, 3H), 3.89 (s, 3H), 5.33 (s, 2H, methylene -H), 6.75 (d, 1H), 6.86 (d, 1H), 7.16 (m, 2H), 7.46 (d, 2H), .77 (d, 1H), 8.04 (d, 2H), 8.64 (d, 2H), MS: $m/z = 431.2 (M+1)$. Anal. Calcd for $C_{25}H_{22}N_2O_5$: C, 69.76; H, 5.15; N, 6.51; O, 18.58; Found: C, 69.70; H, 5.27; N, 6.40; O, 18.44.

2.3.7. 3-((3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)methoxy)-2,4-dimethoxyphenyl (aryl) methanone (8h)

$^1\text{H NMR}$ (CDCl_3) δ ppm: 3.75 (s,3H), 3.84 (s, 6H), 3.89 (s, 3H), 5.33 (s, 2H, methylene -H), 6.75 (d, 1H), 6.86 (d, 2H), 7.26 (d, 1H), 7.46 (d, 3H), 7.77 (d, 1H), 8.04 (d, 2H)MS: $m/z = 477.2 (M+1)$. Anal. Calcd for $C_{26}H_{24}N_2O_7$: C, 65.54; H, 5.08; N, 5.88; O, 23.50; Found: C, 65.90; H, 5.27; N, 5.23; O, 23.24.

2.3.8. 2,4-dimethoxy-3-((3-(p-tolyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl(4-fluoroaryl) methanone (8i)

$^1\text{H NMR}$ (CDCl_3) δ ppm: 2.23 (s, 3H), 3.84 (s, 3H), 3.89 (s, 3H), 5.34 (s, 2H, methylene -H), 6.75 (d, 1H), 6.86 (d, 1H), 7.56 (d, 2H), 7.87 (d, 2H), 8.14 (d, 2H), 8.74 (d, 2H), MS: $m/z = 449.1 (M+1)$. Anal. Calcd for $C_{25}H_{21}F N_2O_5$: C, 66.96; H, 4.72; F, 4.24; N, 6.25; O, 17.84; Found: C, 66.90; H, 4.57; F, 4.30; N, 6.23; O, 17.74.

2.3.9. 3-((3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl)methoxy)-2,4-dimethoxyphenyl(4-fluoroaryl) methanone (8j)


$^1\text{H NMR}$ (CDCl_3) δ ppm: 3.75 (s, 3H), 3.84 (s, 3H), 3.89 (s, 3H), 5.33 (s, 2H, methylene -H), 6.75 (d, 1H), 6.86 (d, 2H), 7.26 (d, 1H), 7.46 (d, 2H), 7.77 (d, 1H), 8.04 (d, 2H), MS: $m/z = 495.1 (M+1)$. Anal. Calcd for $C_{26}H_{23}FN_2O_7$: C, 63.15; H, 4.69; F, 3.84; N, 5.67; O, 22.65; Found: C, 63.10; H, 4.77; F, 3.80; N, 5.53; O, 22.64.

2.3.10. 2,4-dimethoxy-3-((3-phenyl-1,2,4-oxadiazol-5-yl)methoxy)phenyl(4-nitroaryl) methanone (8k)

$^1\text{H NMR}$ (CDCl_3) δ ppm: 3.84 (s, 3H), 3.89 (s, 3H), 5.35 (s, 2H, methylene -H), 6.76 (d, 1H), 6.87 (d, 1H), 7.36 (m, 5H), 7.77 (d, 2H), 8.30 (d, 2H), MS: $m/z = 462.1 (M+1)$. Anal. Calcd for $C_{24}H_{19}N_3O_7$: C, 62.47; H, 4.15; N, 9.11; O, 24.27; Found: C, 62.50; H, 4.17; N, 9.23; O, 24.24.

2.3.11. 3-((3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methoxy)-2,4-dimethoxyphenyl(4-nitrophenyl) methanone (8l)

$^1\text{H NMR}$ (CDCl_3) δ ppm: 3.84 (s, 3H), 3.89 (s, 3H), 5.35 (s, 2H, methylene -H), 6.76 (d, 1H), 6.87 (d, 1H), 7.37 (m, 4H), 7.77 (d, 2H), 8.30 (d, 2H), MS: $m/z = 496.1 (M+1)$: 498.1 (M+3). Anal. Calcd for $C_{24}H_{18}Cl N_3O_7$: C, 58.13; H, 3.66; Cl, 7.15; N, 8.47; O, 22.59; Found: C, 58.10; H, 3.57; Cl, 7.10; N, 8.43; O, 22.54.



a: $R_1 = \text{H}$
b: $R_1 = \text{OMe}$
c: $R_1 = \text{F}$
d: $R_1 = \text{NO}_2$

Scheme 1: Reagents and conditions: (i) chloroacetyl chloride, pyridine, THF, 2h; (ii) Eaton's reagent, aromatic acids, 4h; (iii) Sodium acetate(4.5eq), methanol.

Table - 1: Antibacterial activity data of (3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy) phenyl) aryl methanones(8a-l) Zone of Inhibition in mm


	Bacterial Strains	8a	8b	8c	8d	8e	8f	8g	8h	8i	8j	8k	8l	+ve control Chloroamphenicol
Gram +ve	<i>Bacillus subtilis</i>	-	7	8	-	7	6	-	-	5	-	-	18	22
	<i>Staphylococcus aureus</i>	6	7	12	-	12	6	6	-	-	10	-	16	30
	<i>Escherichia coli</i>	-	8	6	-	-	8	8	7	8	-	8	16	16
Gram -ve	<i>Klebsiella pneumoniae</i>	8	8	-	6	-	-	8	-	-	6	-	14	15
	<i>Pseudomonas aeruginosa</i>	-	-	8	-	-	12	-	-	-	-	-	-	22
	<i>Salmonella typhimurium</i>	-	-	-	-	-	-	-	-	-	-	-	-	28

Values are zones of inhibition in mm. "-" Not sensitive


2.4. Antibacterial Activity by Well Diffusion Method

The antibacterial activity of the synthesized novel (3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)aryl methanones(8a-l) was investigated by following the well diffusion method of Odeyemi and Fagbohun, 2005. Sterile solidified nutrient agar plates were prepared and inoculated with different test bacterial strain by spread plate method. 6mm wells were made in the nutrient agar plates and were filled with the

predetermined concentration of different test samples (10 µg). The loaded plates were then kept for incubation at 37°C for 24 hrs. Antibacterial activity of all the synthesized novel compounds 8a-l were evaluated by measuring the zone of inhibition against the test microorganisms. DMF (Dimethyl formamide) was used as negative control and 10 µg chloramphenicol was used as a positive control. After incubation, the inhibition zone formed around the wells was measured in millimeter. The study was performed in triplicate.



Scheme.2: Reagents and conditions: (i) hydroxylamine hydrochloride, K₂CO₃, EtOH; (ii) chloroacetyl chloride, toluene, reflux



Scheme. 3: Reagents and conditions: (i) K₂CO₃, DMF, reflux

3. RESULTS AND DISCUSSION

3.1. Chemistry

The desired compounds **8a-l** were synthesized as outlined in the scheme-3. Compounds **8a-l** were synthesized by condensing **4a-d** with **7a-f** in presence of potassium carbonate as a base and DMF as solvent. The synthetic route for designed intermediates **4a-d** and **7a-f** were depicted in the scheme 1 and scheme 2 respectively. The desired 3-hydroxy-2, 4-dimethoxybenzophenones **4a-d** were synthesized from 2,6-dimethoxyphenyl 2-chloroacetate **2** and aromatic benzoic acids in Eaton's reagent ((MeSO₃H/ P₂O₅) at 80°C. After the completion of the reaction, The reaction mixture was cooled and diluted with dichloromethane and carefully poured into a beaker containing 10% NaHCO₃, allowed for stirring, the aqueous solution was extracted with CH₂Cl₂ and the combined organic layers were washed with water, brine solution, dried over sodium sulfate and concentrated under reduced pressure to produce a brownish oil as crude product. This crude product was purified by column chromatography on silica gel to afford 3-benzoyl-2,6-dimethoxyphenyl 2-chloroacetate **3a-d**. To a solution of **3a-d** and sodium acetate in methanol was refluxed for 4h, then the reaction mixture was concentrated and extracted with ethyl acetate, the organic layer then washed with water, brine solution, dried over sodium sulfate and concentrated with reduced pressure to get crude product. This crude product was recrystallized using methanol to obtain pure white crystalline solid (3-hydroxy-2,4-dimethoxyphenyl) (phenyl)methanones **4a-d** in excellent yield.

The compounds **7a-f** were synthesized as shown in the scheme 2. Aryl nitriles **5a-f** were converted into respective aryl amidoximes **6a-f** by treating them with hydroxylamine hydrochloride followed by heating. The aryl amidoximes **6a-f** were reacted with chloroacetyl chloride in dry toluene to obtain 5-(Chloromethyl)-3-aryl-1,2,4-oxadiazoles from cyclodehydration of *O*-acylamidoxime. In scheme 1, the formation of **4a-d** was confirmed by ¹H NMR, ¹³C NMR, Mass spectroscopy and elemental analysis. In ¹H NMR, the *para* proton of 2,6-dimethoxy phenoxy group appeared as a triplet at δ 7.20 -7.35, whereas the *meta* proton as a doublet at δ 6.65-7.00. After Friedel-Craft's acylation, *para* and *meta* protons appeared as doublet at δ 7.28 and 6.70 respectively corresponding to hydroxy proton in **4a-d**. The formation of **7a-f** was confirmed by ¹H NMR. The methylene proton and aromatic proton were appeared in the range δ 5.45-5.62 and 7.0-7.75 respectively. The formation of title compounds **8a-l** was confirmed by ¹H NMR and

Mass spectroscopy. The methylene proton appeared in the range δ 5.30 -5.40.

3.2. Biology

In vitro antibacterial activity data of compounds **8a-l** against tested organisms displayed the varying antibacterial activity against used test cultures. The test sample of **8a-l** series was active against *Bacillus subtilis* except **8a**, **8d**, **8g**, **8h**, **8j**, **8k**. **8l** was stronger when compared to the other sample of the series. Sample **8a**, **8b**, **8c**, **8e**, **8f**, **8g**, **8j** - showed the bacteriostatic activity, whereas **8l** showed the strong bactericidal activity against *Staphylococcus aureus*. In case of *Escherichia coli*, **8b**, **8c**, **8f**, **8g**, **8h**, **8i**, **8k** was active and **8l** was stronger as the positive control used. Sample **8a**, **8b**, **8d**, **8g**, **8j**, **8l** showed bacteriostatic activity against *Klebsiella pneumoniae*. Whereas, *Pseudomonas aeruginosa* and *Salmonella typhimurium* showed the resistance against used test sample of **8a-l** series. Overall among the **8a-l** series sample tested for their antibacterial activity against different bacterial strains, **8l** was potent and followed by **8f**, **8c** and **8b**. And the present work concludes that sample **8l** can be used potent as positive control against respective test cultures.

4. CONCLUSIONS

In conclusion, we have reported a facile route for the rapid synthesis of novel (3,5-dimethoxy-4-((3-aryl-1,2,4-oxadiazol-5-yl)methoxy)phenyl)aryl methanones (**8a-l**) from 5-(chloromethyl)-3-aryl-1,2,4-oxadiazole (**7a-f**) with aryl (3-hydroxy-2, 4-dimethoxyphenyl) methanones (**4a-b**) using K₂CO₃. The new molecular framework has shown broad spectrum antibacterial activity which is substantiated by the presence of hydroxyl, carbonyl group and electronegative atoms, among the synthesized compounds (**8a-l**), compound **8l** bearing electronegative atoms respectively in the molecular framework have exhibited potent antibacterial activity, when compared to the standard positive controls.

Acknowledgements

The authors are thankful to the Institution of Excellence (IOE), for providing financial assistance for the synthetic work. The authors are also thankful to University of Mysore, Mysore, for providing laboratory facilities.

5. REFERENCES

1. Weidner-Wells MA, Henninger TC, Fraga-Spano SA, Boggs CM, Matheis M, Ritchie DM, Argentieri DC, Wachter MP and Hlasta DJ. Synthesis and structure-activity relationships of 3, 5-diarylisoxazoles and 3, 5-diaryl-1, 2, 4-oxadiazoles, novel classes of small molecule

- interleukin-8 (IL-8) receptor antagonists. **Bioorg. Med. Chem. Lett.**, 2004; 14: 4307-4311.
- Zhang HZ, Kasibhatla S, Kuemmerle J, Kemnitzer W, Ollis-Mason K, Qiu L, Crogan-Grundy C, Tseng B, Drewe SJ and Cai X. Discovery and structure-activity relationship of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents. 2005; **J. Med. Chem.** 48: 5215-5223.
 - Palmer JT, Rydzewski RM, Mendonca RV, Sperandio D, Spencer JR, Hirschbein BL, Lohman J, Beltman J, Nguyen M and Liu L. Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors. **Bioorg. Med. Chem. Lett.** 2006; 16: 3434-3439.
 - Kumar D, Patel G, Chavers AK, Chang K-H and Shah K. Synthesis of novel 1,2,4-oxadiazole and analogues as potential anticancer agents. **Eur. J. Med. Chem.** 2011; 7(46): 3085-3092.
 - Sangshetti JN and Shinde DB. Synthesis of some novel 3-(1-(1-substituted piperidin-4-yl)-1H-1,2,3-triazol-4-yl)-5-substituted phenyl-1,2,4-oxadiazoles as antifungal agents. **Eur. J. Med. Chem.** 2011; 4(46): 1040-1044.
 - Srivastav Sanchit **IJRAP**, 2011; 2(2): 459-468.
 - Sharma S. **Der pharma Chemica**, 2010; 2(4): 253-263.
 - Nitin Bhardwaj, Saraf SK, Pankaj Sharma and Pradeep kumar. Syntheses, **E-Journal of Chemistry**, 2009; 6(4): 1133-1138.
 - Chandrakantha B, Prakash Shetty, Vijesh Nambiyar, Nishitha Isloor and Arun M. Isloor, **European Journal of Medicinal Chemistry**, 2010; 45: 1206-1210.
 - Jayashankar B, Lokanatha Rai KM, Baskaran N and Sathish HS. **European Journal of Medicinal Chemistry**, 2009; 44: 3898-3902.